Pharvaris (PHVS) Cash from Restructuring (2021 - 2022)
Pharvaris' (PHVS) quarterly Cash from Restructuring came in at -$115903.2 in Q4 2022, up 55.72% YoY from -$74430.1 in Q4 2021, and down 12315.94% on a QoQ basis from $948.79 in Q3 2022.
Pharvaris (PHVS) Cash from Restructuring (2021 - 2022) Analysis & Trends
Pharvaris (PHVS) has 2 years of Cash from Restructuring data on file, last reported at -$115903.2 in Q4 2022.
- Quarterly Cash from Restructuring rose 55.72% year-over-year to -$115903.2 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was -$376709.8 (changed N/A YoY) and the FY2025 annual result came in at -$12.3 million, down 2023.99% from the prior year.
- Cash from Restructuring declined to -$115903.2 in Q4 2022, from $948.79 in the prior quarter.
- In the past five years, Cash from Restructuring ranged from a high of $948.79 in Q3 2022 to a low of -$261755.4 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Pharvaris | 2.29 Bn | 1.92 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -115,903.16 |
| Sep 30, 2022 | 948.79 |
| Dec 31, 2021 | -261,755.43 |